ALNY · 10-Q

Alnylam Pharmaceuticals: AMVUTTRA Drives Q2 Profitability Amid Rising Liabilities

Alnylam Pharmaceuticals filed its 10-Q on July 30, 2026, detailing financial results for the quarter ending June 30, 2026. This filing, now 89 days old, reveals significant growth driven by AMVUTTRA, but also highlights rising liabilities and ongoing legal uncertainties. No subsequent filings have altered this narrative.

What this filing discloses

The 10-Q reports $1.29 billion in revenue for Q2 2026, with net income reaching $164.5 million, a turnaround from a loss in the previous year. AMVUTTRA was the primary growth driver, contributing $1.01 billion to the $1.17 billion in net product revenue, marking a 74% year-over-year increase. Despite this growth, Alnylam faces substantial liabilities, including $1.72 billion related to royalty and development funding, primarily with Blackstone. The filing also notes a rise in cost of goods sold to 25.4% of product revenue, up from 21.1%, due to higher Sanofi royalty tiers.

How this compares with prior filings

Compared to the April 2026 10-Q, the latest filing shows a significant improvement in profitability, driven by AMVUTTRA's sales. However, the increase in liabilities and costs reflects ongoing challenges. The April filing had already outlined the Alnylam 2030 strategy and the company's focus on RNAi therapeutics, but the current filing emphasizes the financial impact of AMVUTTRA's commercial success.

What has happened since

There have been no new filings since the July 30, 2026, 10-Q. Therefore, the financial and strategic landscape described in the filing remains unchanged. The absence of updates suggests that the issues and opportunities highlighted in the filing continue to define Alnylam's current situation.

Why it matters

AMVUTTRA's success has propelled Alnylam into profitability, but the concentration of growth in one product raises concerns about sustainability. The rising cost of goods sold and substantial liabilities could pressure future earnings. Additionally, legal and regulatory challenges, including inquiries from the U.S. Attorney’s Office and FDA, pose risks that could impact financial performance.

What to Watch

| Catalyst | Why It Matters | Timeline |
|----------|----------------|----------|
| AMVUTTRA growth sustainability | Determines future profitability amid rising costs | Ongoing |
| Progress in clinical trials | Impacts future product pipeline and revenue | Ongoing |
| Legal and regulatory developments | Could affect financial outcomes and operations | Ongoing |
| Blackstone funding and liabilities | Influences financial flexibility and obligations | Ongoing |
| Debt management | Affects cash flow and financial health | Ongoing |

Alnylam's current trajectory is shaped by AMVUTTRA's commercial performance, but the company's ability to manage its liabilities and navigate legal challenges will be crucial for sustaining growth.

[Generated on Edgar Tracker · edgartracker.com · Article · GPT 4o]